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Abstract
Amiodarone is a widely used antiarrhythmic drug that can cause the development of steatohepatitis as well as liver fibrosis 
and cirrhosis. The molecular mechanisms of amiodarone-mediated liver injury remain largely unknown. We therefore ana-
lyzed amiodarone-mediated hepatocellular injury in patients with chronic heart failure, in primary hepatocytes and HepG2 
cells. We found that amiodarone-treated patients with chronic heart failure revealed significantly higher serum levels of 
caspase-cleaved keratin-18, an apoptosis biomarker, compared to healthy individuals or patients not receiving amiodarone. 
Furthermore, amiodarone treatment of hepatocytes resulted in apoptosis associated with lipid accumulation and ER-stress 
induction. Liver cell steatosis was accompanied by enhanced de novo lipogenesis which, after reaching peak levels, declined 
together with decreased activation of ER stress. The decline of amiodarone-mediated lipotoxicity was associated with protec-
tive autophagy induction. In contrast, in hepatocytes treated with the autophagy inhibitor chloroquine as well as in autophagy 
gene (ATG5 or ATG7)-deficient hepatocytes, amiodarone-triggered toxicity was increased. In conclusion, we demonstrate 
that amiodarone induces lipid accumulation associated with ER stress and apoptosis in hepatocytes, which is mirrored by 
increased keratin-18 fragment serum levels in amiodarone-treated patients. Autophagy reduces amiodarone-mediated lipo-
toxicity and could provide a therapeutic strategy for protection from drug-induced liver injury.
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Abbreviations
ALT  Alanine aminotransferase
AST  Aspartate aminotransferase
DILI  Drug-induced liver injury
K18  Keratin-18
NAFLD  Non-alcoholic fatty liver disease
NASH  Non-alcoholic steatohepatitis
PHH  Primary human hepatocyte
RLU  Relative light units
ROS  Reactive oxygen species
UPR  Unfolded protein response
Introduction
Drug-induced liver injury (DILI) represents a major cause 
of liver failure and liver transplantation in western countries 
(Chalasani et al. 2015). DILI can occur as acute or chronic 
hepatitis, cholestasis or mixed cholestatic hepatitis (Chalas-
ani et al. 2015). Twenty-six percent of DILI patients reveal 
liver steatosis, with macrovesicular steatosis as the dominant 
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feature in 70% of cases (Kleiner et al. 2014; Rabinowich 
and Shibolet 2015). Drug-induced lipid accumulation in the 
liver is caused by increased de novo lipogenesis, reduced 
very low density lipoprotein secretion and/or drug-mediated 
mitochondrial dysfunction leading to impaired β-oxidation 
of fatty acids. Mitochondrial dysfunction further leads to 
increased production of reactive oxygen species (ROS) 
which elicits the peroxidation of fatty acids and thus the 
generation of pro-inflammatory cytokines. These events 
finally trigger the induction of steatohepatitis with the risk of 
developing liver fibrosis and cirrhosis (Begriche et al. 2011).
Amiodarone, an iodinated benzofuran derivative used 
for preventing and treating of atrial and ventricular arrhyth-
mias, not only induces liver steatosis, but can also trigger 
the development of steatohepatitis and fibrosis (Lewis et al. 
1989; Vassallo and Trohman 2007). Unlike most other cases 
of drug-induced liver injury, amiodarone-mediated liver 
injury can progress despite discontinuation of the drug, 
which might be explained by the long half-life and high 
accumulation of amiodarone in the liver (Lewis et al. 1989; 
Vassallo and Trohman 2007; Chang et al. 1999; Brien et al. 
1987). Steatohepatitis induced by amiodarone was found to 
result in liver cirrhosis in up to 50% of cases (Rigas 1989; 
Farrell 2002; Raja et al. 2009). The underlying mechanisms 
of amiodarone-mediated liver damage, however, remain 
largely unclear.
It could be demonstrated that mice treated with ami-
odarone developed liver steatosis associated with increased 
mitochondrial ROS production and lipid peroxidation (Far-
rell 2002; Berson et al. 1998). Furthermore, endoplasmic 
reticulum (ER) stress was found to play an important role in 
amiodarone-mediated lipotoxicity (Erez et al. 2017; Lom-
bardi et al. 2015). ER stress occurs when protein folding 
demand exceeds folding capacity, a situation which can be 
observed with increased accumulation of fatty acids in the 
liver. ER stress induction is followed by homeostatic signal-
ing reactions, called unfolded protein response (UPR) (Ron 
and Walter 2007). UPR is transduced by different regulators, 
such as inositol-requiring enzyme-1 (IRE1)α and PKR-like 
ER kinase (PERK), both of which are activated by phos-
phorylation as well as by activating transcription factor-6 
(ATF6) which is activated by intramembrane cleavage (Ron 
and Walter 2007). Activated IRE1α splices the mRNA of 
X-box binding protein-1 (XBP1) yielding the transcription 
factor sXBP1. Activated PERK phosphorylates eIF2α result-
ing in the preferential translation of ATF4 and activation of 
the transcription factor CHOP, which can also be activated 
by ATF6 (Ron and Walter 2007). CHOP up-regulates the 
expression of pro-apoptotic molecules of the death-receptor 
and mitochondrial pathway of apoptosis such as TRAIL-
receptor(R)-2, PUMA and BIM and thereby contributes 
to ER-stress-mediated apoptosis (Cazanave et  al. 2011; 
Puthalakath et al. 2007; Jung et al. 2015).
During apoptosis, caspases are activated and cleave vari-
ous substrates including keratin-18 (K18), a major interme-
diate filament protein of hepatocytes. Caspase-cleaved K18 
fragments are released from apoptotic hepatocytes and can 
be detected in sera from patients with liver diseases by an 
enzyme-linked immunosorbent assay (ELISA) detecting a 
caspase-generated neo-epitope of K18 (Bantel et al. 2004). 
In patients with non-alcoholic fatty liver disease (NAFLD) 
serum levels of caspase-cleaved K18 correlated with the 
extent of liver steatosis and liver injury (Joka et al. 2012; 
Tamimi et al. 2011). Moreover, detection of caspase-cleaved 
K18 could predict the requirement of liver transplantation or 
death in patients with DILI (Church et al. 2019). Thus, apop-
tosis plays an important role in drug-induced liver injury 
and outcome.
The reason why some patients with amiodarone treatment 
develop DILI and others not remains completely unclear. 
There is increasing evidence suggesting that autophagy pro-
tects from ER-stress induced cell death (Ogata et al. 2006). 
Autophagy regulates metabolic adaptation and maintains 
cellular homeostasis by removing aggregated and misfolded 
proteins as well as damaged organelles via cytosolic seques-
tration and subsequent lysosomal degradation. Autophagy 
gene (ATG)-related proteins thereby coordinate specific 
steps in autophagy induction. As an initial step, a double-
membrane structure, called autophagosome, is formed. Its 
vacuole membrane then fuses with lysosomal membrane to 
deliver the cytoplasmic contents into autolysosomes, where 
they are degraded. During this process, microtubule-asso-
ciated protein light chain 3 II (LC3-II), which is formed by 
phosphatidylethanolamine conjugation of LC3-I, translo-
cates to the autophagosome membrane, thereby contributing 
to autophagosome formation. Autophagy can be detected by 
LC3-I/-II conversion as well as by decline of p62/sequesto-
some-1 (SQSTM1), a protein that is degraded by autophagy 
(Czaja 2016). It could be demonstrated that autophagy coun-
ter-regulates triglyceride accumulation in the liver (Singh 
et al. 2009). Vice versa, decreased ATG5 expression was 
associated with hepatocellular triglyceride accumulation in 
mice (He et al. 2013).
In the current study we analyzed the mechanisms of ami-
odarone-mediated liver injury. We found that amiodarone-
treated patients with chronic heart failure revealed significantly 
higher serum levels of caspase-cleaved keratin-18 compared 
to healthy individuals or patients not receiving amiodarone. 
Furthermore, amiodarone was found to induce lipid accu-
mulation in hepatocytes associated with increased ER-stress 
and apoptosis. Apoptosis of amiodarone-treated hepatocytes 
time-dependently declined which was paralleled by an increase 
of autophagy. Importantly, amiodarone-mediated cell death 
was significantly increased in hepatocytes deficient for the 
autophagy regulators ATG5 or ATG7. Our results, there-
fore, suggest that amiodarone-treated patients are at risk for 
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ER-stress-mediated apoptotic liver injury and might benefit 
from autophagy-inducing therapeutic strategies.
Materials and methods
Cell culture of HepG2 and primary human 
hepatocytes
HepG2 cells were cultured in Dulbecco’s modified Eagle’s 
medium (Thermo Fisher Scientific, Waltham, MA, US), 
supplemented with 1 g/L of glucose, 10% fetal calf serum 
(Biochrom AG, Berlin, Germany), and 1% penicillin/strep-
tomycin (Merck Millipore, Burlington, MA, US). Primary 
human hepatocytes (PHHs) were isolated as described 
(Kleine et al. 2014). Liver tissue was processed from dif-
ferent donors (n = 8) undergoing partial hepatectomy upon 
obtained written informed consent (approved by the Eth-
ics Committee of Hannover Medical School, #252–2008). 
PHHs were cultured for 36 h in William’s medium E Glu-
taMAX (Thermo Fisher Scientific), supplemented with 1% 
penicillin/streptomycin, 10% fetal calf serum and 100 nM 
of dexamethasone for the first 12 h. HepG2 cells and PHHs 
were treated with 200 µM amiodarone (Sigma-Aldrich, St. 
Louis, MO, US) or the DMSO vehicle control.
RNA preparation and quantitative real‑time PCR
RNA was prepared using the RNeasy kit (Qiagen, Hilden, 
Germany) and cDNA was produced using the QuantiTect 
Reverse Transcription Kit (Qiagen). For expression analysis 
following primers from Sigma-Aldrich were used: SREBP1c 
(forward: 5′-GCG GAG CCA TGG ATT GCA C-3′; reverse: 
5′-CTC TTC CTT GAT ACC AGG CCC-3′), DGAT1 (forward: 
5′-CTC AGA TCC CAC TGG CCT GG-3′; reverse: 5′-GTG 
GAC GTA CAT GAG GAC GGC-3′), CHOP (forward: 5′-CAA 
GAG GTC CTG TCT TCA GATGA-3′; reverse: 5′-TCT GTT 
TCC GTT TCC TGG TTC -3′). Expression of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) mRNA was used 
as internal reference (QuantiTect Primer Assay, Qiagen). 
Real-time RT-PCR was performed in triplicates employing 
a SYBR Green RT-PCR Master Mix (Qiagen) and a QuantS-
tudio system (Thermo Fisher Scientific) under the following 
conditions: 40 cycles of 95 °C for 10 s, 5 s at 55 °C and 240 s 
at 72 °C. Data were analyzed using the comparative (ΔΔCT) 
method with normalization to GAPDH expression.
Detection of cell death, ER‑stress and steatosis 
in hepatocytes
HepG2 cells were seeded on poly-L-lysine (Sigma-Aldrich) 
coated coverslips and incubated with amiodarone or vehi-
cle control. The cells were fixed with 4% paraformaldehyde 
and detection of TUNEL reactivity was performed using the 
In-Situ Cell Death Detection Kit according to the manufac-
turer’s instructions (Roche, Basel, Switzerland). After repeated 
washings, nonspecific binding was blocked with 5% goat 
serum in PBS for 10 min. Cells were then incubated with an 
anti-cleaved caspase-3 antibody (Cell Signaling, Danvers, MA, 
US) for 1 h. Following washing, cells were incubated with 
the Cy3-labeled secondary antibody (Jackson Laboratory, Bar 
Harbor, ME, US) for an additional hour. After final washing 
in PBS, cells were counterstained with DAPI (Thermo Fisher 
Scientific) and covered with fluorescence-mounting medium. 
Cells were microscopically imaged at 200× magnification 
(Olympus BX51 and Cell Software, Shinjuku, Japan).
For immunocytochemical detection of activated IRE1α, 
cells were incubated with a pIRE1α antibody (Abcam, Cam-
bridge, UK) for 1 h after blocking with 5% goat serum. After 
washing, cells were incubated with a Cy3-labeled secondary 
antibody (Jackson Laboratory) for an additional hour. Fol-
lowing final washing, cells were counterstained with DAPI 
(Thermo Fisher Scientific) and covered with fluorescence-
mounting medium. For triglyceride detection, Oil Red O 
staining of cells was performed according to the protocol of 
the manufacturer (Sigma-Aldrich). Triglyceride quantifica-
tion was performed at 400x magnification using Image J 
software (Schindelin et al. 2012).
Immunoblotting
Cell lysates were separated under reducing conditions on 
12 or 15% SDS–polyacrylamide gels and electroblotted to 
a polyvinylidene difluoride membrane. After 1 h of block-
ing in 5% nonfat dry milk powder in TBST, membranes 
were incubated with primary antibodies over night at 4 °C. 
Polyclonal anti-actin and monoclonal anti-p62/SQSTM1 
antibodies were from Santa Cruz (Santa Cruz Biotechnol-
ogy, Dallas, TX, US), monoclonal anti-ATG5 (7C6) and 
monoclonal anti-LC3 antibodies from NanoTools (Teningen, 
Germany), monoclonal anti-ATG7 (D12B11), polyclonal 
anti-cleaved caspase-3, monoclonal anti-CHOP, polyclonal 
anti-p-eIF2α (Ser51), polyclonal anti-eIF2α, polyclonal anti-
p62/SQSTM1 and monoclonal anti-GAPDH antibodies were 
from Cell Signaling. Polyclonal anti-pIRE1α (S724) anti-
body was used from Abcam (Cambridge, UK), polyclonal 
anti-caspase-3 was from R&D (Minneapolis, MN, US) and 
polyclonal anti-LC3B antibody from Novus Biologicals (Lit-
tleton, CO, US). Monoclonal anti-α-tubulin antibody was 
purchased from Sigma-Aldrich.
CRISPR/Cas9‑mediated downregulation of ATG5 
and ATG7
Gene knockouts for human ATG5 (Gene ID: 9474) or ATG7 
(Gene ID: 10533) in HepG2 cells were achieved using 
CRISPR/Cas9 technology. Specific guide RNAs (gRNA) 
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were designed using publicly available CRISPOR software 
(http://crisp or.tefor .net). The ATG5 knockout was stably 
prepared using the LentiCRISPR v2 vector (gift from Feng 
Zhang, Addgene plasmid #52961) (Sanjana et al. 2014), 
while the ATG7 knockout was conditionally prepared using 
the doxycycline-inducible FgH1tUTG and FUCas9Cherry 
plasmids (gift from Marco Herold, Addgene plasmid #70183 
and #70182, respectively) (Aubrey et al. 2015). Sequences 
used for gRNA construction: ATG5 Fw 5′-CAC CGG TGC 
TTC GAG ATG TGT GGT T-3′, Rev 5′-AAA CAA CCA CAC 
ATC TCG AAG CAC C-3′, ATG7: Fw 5′-TCC CGA AGC TGA 
ACG AGT ATC GGC -3′ and Rev 5′-AAA CGC CGA TAC TCG 
TTC AGC TTC -3’.
Recombinant lentiviruses were produced after calcium 
phosphate transfection together with the envelope vector 
PMD2.G and the packaging vectors psPAX2 (provided by 
Dr. D. Trono, University of Geneva, Switzerland) in 293 T 
cells. Viruses were harvested 24 h after transfection, filtered 
through a 0.22 µm membrane (Merck Millipore), and stored 
at − 80 °C until use. HepG2 cells were transduced with the 
desired virus in the presence of 8 µg/mL polybrene. Cell 
clones with a constitutive ATG5 knockout were selected in 
the presence of 2 µg/mL puromycin for 2 weeks. Cells with 
the inducible ATG7 knockout were FACS-sorted according 
to their GFP (FgH1UTG) and mCherry (FUCas9Cherry) 
expression. Control HepG2 lines were prepared in parallel 
by infection with non-gRNA coding lentiviruses. Before the 
experiments, the inducible ATG7 knockout and control cells 
were treated with 2.5 µg/mL doxycycline (Thermo Fisher 
Scientific) for 5 days.
Detection of caspase activity
Caspase-3/-7 activity was measured in triplicate by a lumi-
nescent substrate assay (Caspase-Glo; Promega, Mannheim, 
Germany). Cell extracts were diluted in 50 mM Tris–HCl 
(pH 7.4), 10 mM KCl, and 5% glycerol to reach a final pro-
tein concentration of 0.1 mg/mL. Then, 10 µL of the extracts 
were incubated with 10 µL of the caspase substrate DEVD-
luciferin and luciferase reagent for 2 h at room temperature. 
Luminescence of the samples was measured using a lumi-
nometer (LB 960, Berthold Technologies, Bad Wildbad, 
Germany), yielding relative light units (RLU).
Detection of cell viability
Cell viability was measured using the RealTime-Glo™ MT 
Cell Viability Assay (Promega). HepG2 control, ATG5 or 
ATG7 knockout cells were plated in white 96-well assay 
plates (5 × 103 cells/well). The MT Cell Viability Substrate 
and NanoLuc® Enzyme were added to the cultures together 
with 200 µM of amiodarone or with the drug vehicle con-
trol. The luminescence signal was measured at 6 h using 
the GloMax Explorer Multimode Microplate Reader (Pro-
mega). Results are presented as percentage (mean ± SEM) 
of amiodarone-treated cells normalized to DMSO-treated 
control cells from two separate experiments performed with 
4–5 replicates.
Serological detection of caspase‑cleaved keratin‑18
For quantitative measurement of the caspase-generated 
neo-epitope of K18, we used the M30-Apoptosense ELISA 
(Peviva, Bromma, Sweden) according to the manufactur-
er’s instructions as described (Bantel et al. 2004; Joka et al. 
2012). Sera from patients with chronic heart failure (n = 15) 
either treated (n = 6) or non-treated (n = 9) with amiodarone 
(200 mg/day) as well as from healthy persons (n = 13) were 
analyzed in duplicate for caspase-mediated K18 cleavage 
fragments. At the time of blood analyses patients received 
amiodarone for at least 4 months. Patients with or without 
amiodarone treatment revealed no significant differences in 
age (75.3 ± 3.5 vs. 72.2 ± 3.2 years), sex (83.3% vs. 77.8% 
of male), type 2 diabetes (33.3% vs. 33.3%), body mass 
index (BMI; 27.4 ± 1.5 vs. 28.8 ± 1.0) as well as in the use 
of lipid lowering or anti-coagulative drugs. The study was 
performed according to the Ethics Committee of Hannover 
Medical School.
Statistical analyses
Statistical analyses of the cell culture experiments were per-
formed using paired t-test (equal distribution) or one-sample 
t-test (mRNA expression compared to untreated control). 
For statistical analysis of AST/ALT and caspase-cleaved 
K18 serum levels unpaired t-test (equal distribution) and of 
clinical characteristics Mann Whitney’s U test (non-equal 
distribution) were performed using GraphPad Prism 5.0 
(GraphPad Software, La Jolla, CA, US). Data are presented 
as mean ± standard error of the mean (SEM). A p-value of 
less than 0.05 was considered significant.
Results
Amiodarone‑treated patients with chronic heart 
failure reveal increased caspase activation, which 
is mirrored by amiodarone treatment of isolated 
hepatocytes
In initial experiments we asked whether amiodarone treat-
ment of patients with chronic heart failure results in apop-
totic liver injury. We first compared alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) levels 
in sera from patients with chronic heart failure either receiv-
ing (n = 6) or not receiving (n = 9) amiodarone treatment 
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(Fig. 1a). We found only marginally and within the normal 
range elevated AST (24.2 ± 1.9 U/L) and ALT (22.2 ± 3.6 
U/L) levels in amiodarone-treated patients compared to those 
not receiving amiodarone (23.0 ± 1.8 U/L and 18.6 ± 2.2 
U/L) which was, however, not significant. Next, we analyzed 
the serum levels of caspase-cleaved K18. The intermedi-
ate filament protein K18 is expressed in hepatocytes and 
cleaved during apoptosis by caspases. A cleavage-generated 
K18 fragment is released in the blood stream and has previ-
ously been established as a reliable biomarker of apoptotic 
liver injury (Bantel et al. 2004; Joka et al. 2012; Tamimi 
et al. 2011). Using a specific ELISA (Fig. 1b), we interest-
ingly found that heart failure patients receiving amiodarone 
revealed significantly higher serum levels of caspase-cleaved 
K18 (n = 6; 293.6 ± 58.4 U/L) compared to patients without 
amiodarone therapy (n = 9; 172.1 ± 17.9 U/L) or healthy 
control individuals (n = 13; 174.8 ± 14.0 U/L). Heart failure 
patients without amiodarone treatment showed similar levels 
of caspase-cleaved K18 as healthy controls, indicating that 
heart failure per se did not influence liver injury in those 
patients. Moreover, chronic heart failure has been previously 
associated with necrotic rather than apoptotic cell death 
Fig. 1  Amiodarone treatment 
results in liver cell apoptosis. 
a Detection of serum AST 
and ALT levels in chronic 
heart failure patients with or 
without amiodarone treatment. 
Patients with chronic heart 
failure treated with amiodarone 
revealed slightly elevated ami-
notransferase levels compared 
to patients without amiodarone 
treatment, which was, however, 
not significant. b Detection 
of caspase-cleaved keratin-18 
(K18) in sera from chronic heart 
failure patients. Treatment of 
chronic heart failure patients 
with amiodarone resulted in 
significantly higher serum levels 
of caspase-cleaved K18 com-
pared to patients not receiving 
amiodarone or healthy persons. 
c Amiodarone time-dependently 
induces caspase-3/-7 activity in 
HepG2 cells. Cells were treated 
for the indicated time with 
amiodarone (200 µM), before 
caspase activity was measured 
by a luminometric substrate 
assay. Data were obtained from 
5 independent experiments. d 
Immunocytochemistry of cas-
pase-3 activation and TUNEL 
staining after amiodarone 
treatment of HepG cells. Cells 
were either left untreated or 
incubated for 4 h with 200 µM 
amiodarone. Merged images 
were produced by overlay-
ing caspase-3 (red), TUNEL 
(green) and nuclear DAPI (blue) 
staining. Bars = 100 µm. Sig-
nificances indicated above the 
bars refer to control. *p < 0.05, 
**p < 0.01, n.s. = non-significant 
(colour figure online)
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(Bechmann et al. 2010). These data, therefore, indicate that 
amiodarone treatment of patients with chronic heart failure 
results in apoptotic liver injury, which can be detected with 
high sensitivity using caspase-cleaved K18.
To further investigate the role of apoptosis for amiodar-
one-mediated liver toxicity, we analyzed the activation of 
effector caspase-3/-7 in amiodarone-treated HepG2 cells 
using a luminometric substrate assay. Initial dose-finding 
experiments revealed effective caspase activation with 
200  µM amiodarone (data not shown), a concentration 
which was found to cause hepatotoxicity in previous stud-
ies (Erez et al. 2017; Fromenty 1990b) and, therefore, used 
for further experiments. Compared to untreated control, 
treatment of HepG2 cells with amiodarone significantly 
increased caspase-3/-7 activation with a maximum at 4 h 
(3496.7 ± 576.8 RLU vs. 83.6 ± 31.4 RLU; p < 0.01), fol-
lowed by a decline at 6 and 8 h of treatment (2042.8 ± 314.1 
RLU and 1281.8 ± 196.6 RLU; Fig. 1c). Double staining for 
active caspase-3 and TUNEL reactivity revealed that cas-
pase activation in HepG2 cells was indeed associated with 
apoptosis following 4 h of amiodarone treatment (Fig. 1d).
Amiodarone induces lipid accumulation 
in hepatocytes
Since lipid accumulation can trigger pathways of apoptotic 
cell death, we next analyzed amiodarone-mediated hepato-
cyte steatosis by Oil Red O staining of triglycerides. We 
found that amiodarone induced lipid accumulation in HepG2 
cells, which was most strongly pronounced after 4 and 6 h of 
incubation (4.4 ± 1.5 and 4.3 ± 1.0 fold increase compared 
to untreated control; Fig. 2a, b), similar to our observation 
of maximal caspase activation (Fig. 1c). Hepatocyte steato-
sis significantly (p < 0.05) declined after 8 h of amiodarone 
treatment (3.6 ± 1.0 fold increase compared to untreated con-
trol) compared to 6 h of amiodarone incubation (Fig. 2a, b).
Based on these observations, we analyzed the potential 
effect of amiodarone on de novo lipogenesis in hepatocytes. 
We found that amiodarone induced mRNA expression of 
sterol-regulatory element-binding protein-1c (SREBP1c), a 
major transcription factor of lipogenesis, in a similar time 
frame as observed for amiodarone-induced lipid accumula-
tion. SREBP1c expression significantly (p < 0.05) increased 
from 2 h to 4 and 6 h of amiodarone incubation (5.9 ± 0.7 
fold increase compared to untreated control) followed by a 
decline at 8 h of treatment (Fig. 2c). Since diacylglycerol-
acyltransferase-1 (DGAT1) is a critical regulator of triglyc-
eride formation, we also assessed the transcription of this 
enzyme in amiodarone-treated vs. untreated HepG2 cells. 
Like with SREBP1c, we found an increase in DGAT1 mRNA 
peaking at 6 h after amiodarone treatment (2.1 ± 0.4 fold 
increase compared to control) (Fig. 2c). Thus, amiodarone-
induced lipid accumulation in hepatocytes is associated 
with enhanced mRNA expression of the lipogenic regula-
tors SREBP1c and DGAT1.
Amiodarone induces endoplasmic reticulum stress 
in hepatocytes
To further explore the pathways of amiodarone-mediated 
lipotoxicity, we analyzed the effect of amiodarone on ER-
stress induction. We found that amiodarone treatment of 
HepG2 cells led to a time-dependent phosphorylation and, 
hence, activation of the ER-stress regulator IRE1α which 
was most pronounced after 4 h, as demonstrated by Western 
blot analysis (Fig. 3a). Activation of IRE1α was confirmed 
by immunocytochemistry which showed an increased num-
ber of HepG2 cells positive for phosphorylated IRE1α stain-
ing after 4 h of amiodarone treatment compared to untreated 
control cells (Fig. 3b). Furthermore, enhanced IRE1α activa-
tion was associated with a decreased cell number (Fig. 3b).
In addition to IRE1α, we analyzed eIF2α, a subunit of 
the eukaryotic translation initiation factor 2, which is phos-
phorylated by PERK during the unfolded protein response 
resulting in a global downregulation of protein synthesis. 
Phosphorylation of eIF2α was visible after 2–4 h of ami-
odarone treatment and thereafter decreased (Fig. 3a). In 
accordance, expression of the downstream transcription 
factor CHOP was strongly induced at the protein (Fig. 3a) 
and mRNA level (Fig. 3c) by amiodarone treatment. CHOP 
transcripts reached a peak expression at 6 h of amiodarone 
incubation (34.9 ± 9.1 fold increase relative to untreated con-
trol, p < 0.05) and thereafter declined (Fig. 3a, c).
Amiodarone triggers protective autophagy 
in hepatocytes
Since lipid accumulation in hepatocytes is associated with 
autophagy induction, we asked whether amiodarone treat-
ment of HepG2 cells also results in enhanced autophagy. 
Amiodarone indeed induced autophagy, as indicated by a 
decrease of p62/SQSTM1 and increased LC3B-I/II conver-
sion, which are two events required for autophagosome for-
mation (Fig. 4a). Compared to amiodarone treatment alone, 
combined treatment of HepG2 cells with amiodarone and 
the autophagy inhibitor chloroquine for 4 or 6 h resulted in 
enhanced caspase-3 activation (Fig. 4b). In contrast to ami-
odarone, treatment with chloroquine alone did not induce 
caspase-3 activation (Fig. 4b).
To further analyze a potentially protective role of 
autophagy in amiodarone-mediated liver cell toxicity, 
we generated HepG2 cells deficient for autophagy-regu-
lating genes, such as ATG5 and ATG7, using CRISPR/
Cas-9 technology. As demonstrated by Western blot analy-
sis (Fig. 4c), HepG2 cells deficient for ATG5 or ATG7 
revealed a lower level of autophagy, as indicated by a p62/
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SQSTM1 stabilization and reduced LC3B-I/II conversion 
compared to the respective control cells. Amiodarone 
treatment of ATG5-deficient HepG2 cells for 6 h resulted 
in significantly (p < 0.01) lower cell viability compared 
to control cells (Fig. 4d). Similarly, also ATG7 deficiency 
resulted in enhanced cell death of HepG2 cells after 6 h of 
amiodarone treatment as compared to the respective con-
trol cells (Fig. 4d). Thus, amiodarone-mediated toxicity 
was attenuated by its autophagy-inducing property.
Amiodarone‑induced ER stress, apoptosis 
and autophagy in primary human hepatocytes
To further verify our results obtained in HepG2 cells, we 
analyzed amiodarone-mediated toxicity and autophagy 
induction in primary human hepatocytes (PHHs) from differ-
ent donors (n = 8). In line with our findings in HepG2 cells, 
we observed a significant (p < 0.01) increase of caspase-3/-7 
activity in PHHs after 2 h of treatment with amiodarone 
(200 µM) compared to untreated controls (1549.3 ± 304.1 
RLU vs. 315.6 ± 120.8 RLU). Thereafter, caspase activity 
Fig. 2  Amiodarone induces 
hepatocyte steatosis and 
increased expression of lipo-
genic regulators. a, b Triglyc-
eride accumulation in HepG2 
cells, as assessed by Oil Red 
O staining, was induced after 
2–6 h of amiodarone treatment 
(200 µM) followed by a decline 
after 8 h. c Transcription of the 
lipogenic regulators SREBP1c 
and DGAT1 was induced by 
amiodarone treatment of HepG2 
cells with peak levels at 6 h and 
a decrease at 8 h. Data were 
obtained from 3 independent 
experiments. Significances 
indicated above the bars refer to 
control. *p < 0.05
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again declined (Fig. 5a). Western blot analysis confirmed 
a significant increase of active caspase-3 in PHHs at 2 h 
of amiodarone treatment followed by a decline at 4–8 h 
(Fig. 5b). In addition, increased phosphorylation of ER-
stress regulators, i.e., IRE1α and eIF2α, could be observed 
at 2 h of PHH treatment with amiodarone, followed by a 
decline at 4–8 h (Fig. 5c). Decreased ER stress was asso-
ciated with an increase of autophagy at 4 h of amiodar-
one-treated PHHs indicated by a decline of p62/SQSTM1 
(Fig. 5d).
Discussion
Amiodarone is a frequently used antiarrhythmic drug known 
to induce acute and chronic liver injury (Grimaldi-Bensouda 
et al. 2018; Björnsson 2015). Due to its long half-life and 
lipophilic structure, it persists in the liver for longer periods. 
Liver toxicity may therefore occur even after discontinuation 
of the therapy (Brien et al. 1987). The mechanisms leading 
to amiodarone-mediated liver injury have not yet been fully 
elucidated.
In the current study, we observed significantly higher 
serum levels of caspase-cleaved K18 in patients with 
chronic heart failure treated with amiodarone compared 
to those without amiodarone treatment, suggesting that 
amiodarone induces apoptotic liver injury. In contrast, 
aminotransferase levels were within the normal range in 
both groups. The discrepancy between aminotransferases 
and this apoptosis marker might be explained by a pre-
sumably higher sensitivity of the M30 assay and stabil-
ity of the K18 fragments (Bantel et al. 2004; Feldstein 
et al. 2009; Olofsson et al. 2007; Cummings et al. 2006). 
Serological detection of caspase-cleaved K18 therefore 
allows the early detection of apoptotic liver injury despite 
normal aminotransferases, as shown in previous studies 
(Bantel et al. 2004; Kronenberger et al. 2005). Moreover, 
amiodarone-treated patients revealed mean serum levels 
of caspase-cleaved K18 > 200 U/L, a cut-off value which 
was closely related to the presence of non-alcoholic stea-
tohepatitis (NASH) and fibrosis in NAFLD studies (Liebig 
et al. 2019; Feldstein et al. 2009). In contrast, patients 
without amiodarone treatment showed mean serum levels 
of caspase-cleaved K18 < 200 U/L, comparable to those 
of healthy individuals. Our in vitro analyses demonstrate 
Fig. 3  Amiodarone induces ER 
stress. a Western blot analysis 
demonstrated that amiodarone 
treatment (200 µM) of HepG2 
cells results in the phosphoryla-
tion of IRE1α and eIF2α as well 
as in increased expression of 
the transcription factor CHOP. 
Phosphorylation of eIF2α and 
CHOP expression increases up 
to 4–6 h followed by a decline 
at 8 h of treatment. b Immuno-
cytochemical detection of phos-
phorylated and hence activated 
IRE1α in HepG2 cells treated 
for 4 h with amiodarone further 
confirms ER stress induction. c 
Quantification of CHOP mRNA 
after amiodarone treatment 
of HepG2 cells compared to 
untreated control cells. Data 
were obtained from 4 independ-
ent experiments. Bars = 100 µm. 
*p < 0.05, **p < 0.01
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that amiodarone indeed induced caspase-3/-7 activation in 
hepatocytes. Hepatocellular caspase activation was associ-
ated with TUNEL reactivity, indicating that cell death is 
mediated by apoptosis.
Since amiodarone is known to induce liver steatosis which 
sensitizes hepatocytes for apoptosis (Rabinowich and Shi-
bolet 2015; Malhi et al. 2007; Vitins et al. 2014), we asked 
whether amiodarone-induced apoptosis is associated with 
Fig. 4  Amiodarone treatment triggers autophagy. a Western blot 
analysis revealed decreased p62/SQSTM1 expression and increased 
LC3B-I/II conversion in HepG2 cells treated with amiodarone for 
2–8  h. b Compared to amiodarone treatment alone, pretreatment of 
HepG2 cells with the autophagy inhibitor chloroquine increased cas-
pase-3 activation at 4 and 6 h of amiodarone treatment (left panel). 
The vertical lines indicate juxtaposition of non-adjacent lanes from 
the same blot. In contrast to amiodarone, chloroquine itself did not 
induce caspase-3 activation (right panel). c Compared to the cor-
responding control cells, ATG5- or ATG7-deficient HepG2 cells 
revealed decreased autophagy as shown by p62/SQSTM1 stabiliza-
tion and lack of LC3B-I/-II conversion in Western blot analyses. d 
ATG5- or ATG7-deficiency resulted in enhanced cell death of HepG2 
cells after 6 h of amiodarone treatment as compared to control cells. 
**p < 0.01
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lipid accumulation. We observed that amiodarone-mediated 
hepatocellular steatosis occurred earlier than caspase-3/-7 
activation, suggesting that amiodarone-mediated lipid accu-
mulation might trigger apoptosis. Amiodarone was shown 
to accumulate in hepatic mitochondria and to inhibit the 
electron transport chain (Fromenty et al. 1990a) which can 
result in ROS formation and apoptotic cell death. Amiodar-
one-mediated mitochondrial dysfunction also causes inhibi-
tion of β-oxidation of fatty acids which leads to triglyceride 
accumulation and subsequent liver steatosis (Fromenty et al. 
1990b). Furthermore, lipid accumulation might be caused by 
amiodarone-induced expression of genes involved in lipo-
genesis (Anthérieu et al. 2011; Vitins et al. 2014). Indeed, 
we observed an increased mRNA expression of SREBP1c, 
a major transcription factor of de novo lipogenesis, as well 
as of DGAT1, an enzyme involved in triglyceride formation, 
in amiodarone-treated hepatocytes. Interestingly, transcripts 
for both regulators of lipogenesis were up-regulated by ami-
odarone in a similar time-dependent manner as observed for 
caspase activation.
Accumulated fatty acids trigger ER stress which leads 
to UPR activation (Cao et al. 2012). ER stress is not only a 
consequence, but can also cause lipid accumulation (Henkel 
and Green 2013). In this context, it could be demonstrated 
that CHOP-deficient mice revealed reduced amiodarone-
mediated hepatic lipid accumulation and apoptosis (Erez 
et al. 2017). However, although pharmacologic inducers 
of ER stress such as tunicamycin cause liver steatosis in 
mice, they can suppress hepatic lipid synthesis suggest-
ing that ER-stress-induced hepatic steatosis does not result 
from de novo lipogenesis (Erez et al. 2017; Rutkowski et al. 
2008). Instead, ER stress has been shown to inhibit VLDL 
secretion, thereby contributing to lipid accumulation (Ota 
et al. 2008). In our study we could demonstrate that ami-
odarone triggers lipogenesis, indicated by up-regulation 
of SREBP1c and DGAT1, which was closely associated 
with lipid accumulation and activation of UPR branches 
(IRE1α, PERK/eIF2α) and consecutive CHOP induction in 
hepatocytes. CHOP can trigger apoptosis by up-regulation 
of pro-apoptotic molecules including TRAIL-R2, PUMA 
and BIM (Cazanave et al. 2011; Puthalakath et al. 2007; 
Jung et al. 2015). Vice versa, CHOP-deficient hepatocytes 
are protected from fatty acid-induced apoptosis (Cazanave 
et al. 2011). Furthermore, IRE1α-mediated activation of 
Fig. 5  Amiodarone-induced apoptosis, ER-stress and autophagy in 
primary human hepatocytes. a Treatment of PHHs (n = 8 donors) 
with amiodarone (200  µM) for 2  h significantly increased cas-
pase-3/-7 activity followed by a significant decline at 4–8 h of treat-
ment. b Western blot analysis confirmed a significant increase of 
activated caspase-3 after 2  h of PHH treatment with amiodarone, 
which then decreased at 4–8 h of treatment. c ER stress is triggered 
in PHHs by amiodarone, indicated by phosphorylation of IRE1α and 
eIF2α, which peaked at 2  h of treatment and thereafter declined. d 
Autophagy was induced at 4–8 h of amiodarone treatment of PHHs as 
indicated by decreased p62/SQSTM1. Significances indicated above 
the bars refer to control. *p < 0.05, **p < 0.01
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c-Jun-terminal kinase (JNK) leads to down-regulation of 
anti-apoptotic molecules and induction of BIM/BAX-medi-
ated apoptosis (Lei and Davis 2003; Yamamoto et al. 1999; 
Rodriguez et al. 2012). JNK can also up-regulate TRAIL-
R2 expression, thereby sensitizing hepatocytes for TRAIL-
induced apoptosis (Malhi et al. 2007). ER stress associated 
apoptosis can therefore be mediated by the death receptor as 
well as by the mitochondrial death pathway.
In our study, we observed a decline of ER stress in the 
course of amiodarone treatment, as shown by decreased 
eIF2α phosphorylation and CHOP expression in hepato-
cytes. In accordance with declining ER stress, we found 
decreased caspase-3/-7 activation in amiodarone-treated 
hepatocytes. The reason for the time-dependent decline in 
amiodarone-mediated toxicity remains unclear. Recently, 
enhanced ER stress and liver injury have been associated 
with impaired autophagy in murine and human NAFLD 
which, conversely, could be reduced by autophagy induc-
tion (González-Rodríguez et al. 2014; Tanaka et al. 2016; 
Lin et al. 2013). Accordingly, mice with hepatocellular 
autophagy (ATG7)-deficiency revealed increased oxidative 
stress-induced activation of JNK and caspases as well as 
enhanced hepatocyte apoptosis (Wang et al. 2010; Amir 
et al. 2013; Römermann et al. 2020). Vice versa, treatment 
of patients with fibrinogen storage disease, which is char-
acterized by the accumulation of fibrinogen aggregates and 
enhanced ER stress in the liver, with the autophagy inducer 
carbamazepine resulted in increased autophagy in the liver 
and decreased serum levels of caspase-cleaved K18 (Puls 
et al. 2013). Developing of strategies to minimize the risk of 
DILI is of great importance (Walker et al. 2020).
We therefore asked whether autophagy induction in the 
course of amiodarone treatment might counter-regulate its 
liver toxicity. Indeed, autophagy was induced in HepG2 cells 
and most strongly pronounced at 8 h of amiodarone treat-
ment, paralleled by decreased ER-stress and caspase-3 acti-
vation. Vice versa, inhibition of autophagy by chloroquine 
resulted in enhanced caspase-3 activation in amiodarone-
treated hepatocytes. The protective role of autophagy was 
further underlined by our observation that amiodarone-
mediated hepatocellular toxicity was significantly increased 
in HepG2 cells deficient for the autophagy genes ATG5 or 
ATG7. Similarly, it was demonstrated that autophagy inhi-
bition increased amiodarone-mediated apoptosis in lung 
epithelial cells (Lee et al. 2013). Our data therefore suggest 
that amiodarone-mediated toxicity can be counter-regulated 
by autophagy induction. Amiodarone-mediated autophagy 
induction has been associated with ROS-induced adenine 
monophosphate-activated protein kinase (AMPK) activa-
tion, which in turn leads to inhibition of mTOR, a nega-
tive regulator of autophagy (Zhang et al. 2009; Choi et al. 
2001). In this context, it is interesting to note that autophagy 
induction by the mTOR inhibitor rapamycin protects against 
apoptosis and acetaminophen-induced liver toxicity (Ravi-
kumar et al. 2006; Ni et al. 2012). Pharmacological pro-
motion of autophagy might therefore represent a promising 
therapeutic strategy to alleviate drug-induced liver injury.
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